Iktos
Artificial Intelligence for New Drug Design
Feb. 28, 2021
Courtesy ofIktos
Iktos Develops a Technology Platform for Deep Learning-Based de novo Drug Development
Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.
Big data and artificial intelligence (AI) can significantly accelerate many processes and make them more efficient. The Paris, France-based start-up Iktos is developing a proprietary AI technology for ligand and structure-based de novo drug design, focusing on multi parametric optimization (MPO). Yann Gaston-Mathé, co-founder and CEO of Iktos, explains the company’s technologies and provides an outlook on the further development of the company.
Most popular related searches
Stay in the loop!
Select your areas of interest to receive industry updates.